Ergot alkaloids have also been implicated in peripartum cerebral angiopathy
Postpartum cerebral angiopathy
is a rare condition for which no incidence rate is cited in the literature (Konstantinopoulos, Mousa, Khairallah, & Mtanos, 2004).
The patient was elderly; however, no foci of prior hemorrhage were noted, which argued against cerebral amyloid angiopathy
Chronic endothelial damage plays an important role in the development of angiopathy
in diabetes mellitus.
Cerebral amyloid angiopathy
can be differentiated from CADASIL because it presents in older individuals, and staining with Congo red is negative in the latter condition.
Microbleed assessment on T2 *-weighted MRI may serve as a possible marker of both cerebral amyloid angiopathy
and hypertensive vasculopathy progression," Dr.
Greenberg, a neurologist with the Hemorrhagic Stroke Research Program at Massachusetts General Hospital and Harvard Medical School, Boston, noted that advances in detection are coming at a time when the incidence of hypertensive vasculopathy and cerebral amyloid angiopathy
are expected to rise as the Baby Boom generation continues to age.
In a study involving the postmortem neuropathologic evaluation of brains from 113 subjects (61% women), the incidence and severity of cerebral amyloid angiopathy
(CAA) was highest in the occipital region, followed by the frontal, hippocampal, and frontobasal areas.
The CONJUMAB-A platform is applicable to a broad range of diseases including, Alzheimer's, Parkinson's, Huntington's, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy
, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration and Peripheral Amyloidosis.
As they observed the mice, they found that the levels of amyloid-beta proteins, which are key markers of Alzheimer's progression in the brain, were reduced by nearly two-thirds (62%), and cerebral amyloid angiopathy
(CAA, another marker of the disease in which the amyloid proteins harden the brain's blood vessel walls) was improved by 86 percent.
Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has been the subject of a completed Phase III clinical trial in North America and is currently being studied in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy
, has been studied in a completed Phase IIa clinical trial.
Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy
, has completed a Phase IIa clinical trial.